Celestia Higano, MD

Articles

Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

September 1st 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Dr. Higano on Changes Being Made in the Field of Prostate Cancer

August 22nd 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the changes being made in the field of prostate cancer.

Dr. Higano on Combinations With Radium-223 for Prostate Cancer

August 18th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses risks associated with combining radium-223 dichloride (Xofigo) for patients with prostate cancer.

Dr. Higano on Radium-223 for Prostate Cancer

June 27th 2017

Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Dr. Higano Discusses PARP Inhibitors in Prostate Cancer

April 25th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses PARP inhibitors in prostate cancer.

Dr. Higano on Docetaxel for Hormone-Sensitive Prostate Cancer

April 14th 2017

Celestia Higano, MD, professor of Medicine and Urology, University of Washington, member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results of docetaxel (Taxotere) versus hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

x